Q4 2024 Management View CEO Brian Lian highlighted 2024 as an exceptionally busy year, with successful results from four studies, including the Phase 2 VENTURE trial for subcutaneous VK2735, which ...

Viking Therapeutics is a clinical-stage biotech company focused on developing weight-loss therapies. Read why I rate VKTX ...

Viking Therapeutics stock plunged late Wednesday on an earnings report that included mostly incremental updates for its ...

Viking Therapeutics Inc (VKTX) reports significant R&D progress and financial bolstering despite increased losses and operational challenges.

Market uncertainty makes investors nervous about investing in speculative industries. But Wall Street has high hopes for ...

Viking Therapeutics announces its fourth-quarter financial results after Wednesday's closing bell. Here's a look at the ...

When the company reported VK2735's phase 2 results last year, the stock jumped 121% in one trading session. Viking gave back ...

Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced its ...

Shares of Viking Therapeutics (VKTX) slid 8% post-market after the biotech company issued its Q4 earnings report and a pipeline update. Read more here.

13-Week Study to Evaluate the Safety and Efficacy of Oral VK2735 Dosed Once Daily SAN DIEGO, Jan. 8, 2025 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage ...

Viking held cash, cash equivalents and short-term investments of $903M, compared to $362M as of December 31, 2023. 2024 ...